Shionogi has acquired Tetra Therapeutics, the developer of the BPN14770 treatment candidate for fragile X syndrome and Alzheimer’s disease.| Fragile X News Today
Tetra Therapeutics’ investigational oral therapy BPN14770 safely and effectively improved cognitive function in men with fragile X syndrome.| Fragile X News Today